Skip to main content
. Author manuscript; available in PMC: 2015 Aug 21.
Published in final edited form as: Immunity. 2014 Jul 24;41(2):296–310. doi: 10.1016/j.immuni.2014.06.014

Figure 6. TLR4 is critical for indomethacin-induced intestinal injury as well as IPA effects on permeability in vivo.

Figure 6

(A) Representative Hematoxylin and eosin staining of vehicle (-Indo) and indomethacin (Indo) treated Nr1i2−/− /Tlr4−/− mice jejunum cross-sections (n=6 per group).

(B) Jejunal MPO activity (unit/g of total protein) in Nr1i2−/− and Nr1i2−/− /Tlr4−/− mice treated with indomethacin (n=6 per group). *P ≤ 0.005 (One-way ANOVA with Sidak’s multiple comparison test).

(C) Serum FITC-dextran recovery following oral gavage of IPA (20 mg/kg/day) and indomethacin (see schematic ) in Tlr−/− (n = 9) mice.

(D) Serum FITC-dextran recovery following oral gavage of IPA (20 mg/kg/day) and KDO2 200μg/day (see schematic) in conventional mice (Nr1i2+/+ ) and commensal depleted (CD) mice (Nr1i2+/+ ) (n = 8 per group). All graphs show mean values ± s.e.m. *P ≤ 0.004 ,**P ≤ 0.05; n.s. not significant (Two-way ANOVA with Tukey’s multiple comparison test).